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Abstract:  Microglia are the surveillant immune cells of the brain, and as such they help protect 
the nervous system by clearing pathogens and dead cells, producing neurotrophic factors, and 
maintaining homeostasis. As guardians of the brain, microglia may be especially important in 
neural repair following injuries such as ischemic stroke, a disease which takes 6.2 million lives 
worldwide every year. Although microglia respond to tissue injury after stroke, they 
are themselves also vulnerable to ischemic death. Protecting microglia from ischemia-induced 
cell death could promote brain tissue restoration after stroke. Given the well-known anti-
inflammatory and protective effects of adenosine (Ado) on other cell types following ischemia, 
we investigated the effects of Ado on MG during ischemia. Here, we provide preliminary 
evidence in an in-vitro model that exogenous Ado can attenuate MG cell death during stroke. 
Using cultured microglia-like BV2 cells in oxygen-glucose deprivation (OGD) conditions to 
mimic ischemic stroke, we found that application of 500 µM Ado during OGD significantly 
(p=.00002) reduced cell death (Cell Death Ratios- Control: 0.12±0.03, OGD: 0.23±0.08, 
OGD+500µM Ado: 0.08±0.03). Preliminary evidence also indicates that Ado (500 µM) protects 
parenchymal microglia against OGD in a neonatal mouse hippocampal slice model. We are 
currently investigating the receptor(s) (R) responsible for mediating the protection.  Preliminary 
studies using 35 nM 2-Chloro-N6-cyclopentyladenosine (an A1-R agonist) and 200 nM 
CGS21680 (an A2A-R agonist) indicate that neither A1-R nor A2A-R alone are sufficient to 
cause the protective effects of Ado (p=0.70 and p=0.34 respectively). Using 2 nM ZM 241385 
(an A2A-R antagonist) was also not able to block the protective effects of adenosine, indicating 
that the A2A-R is not necessary for this protective effect. To continue these experiments, we 
have begun to extend our project into a line of primary microglial cells, to create a model that is 
even closer to resident microglia during stroke. Moving forward, using both Ado-R agonists and 
antagonists to identify the specific Ado-R(s) protecting microglia during stroke would not only 
suggest a new role for adenosine in microglial signaling, but could also give rise to a new 
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Microglia: My project centers on microglia, the innate immune cells of the central nervous 
system (CNS). These cells are responsible for surveilling the CNS, extending their processes 
throughout the CNS to detect potential threats. When they do detect a threat, they become 
“activated”, retracting their processes and triggering a cascade of inflammation to protect the 
CNS. Although traditionally thought of as the first line of defense for the brain against invading 
pathogens, these cells actually contribute to a wide range of different functions besides the 
protective capabilities described above. Microglial cells can be thought of as the “plumbers” of 
the CNS, as they regulate the formation of blood vessels throughout the brain. They also seem to 
play a crucial role in cell death, acting as “morticians” by both helping to induce apoptosis and 
clearing dead cells. Finally, many recent studies have elucidated their role as “electricians” 
responsible for shaping neuronal circuits by phagocytosing individual synapses (neuron to 
neuron connections) (Eyo and Dailey, 2013). The focus of many neuroscientists now is trying to 
understand the roles of these varied functions in disease, and recent cutting-edge work has 
focused on microglial cells during diseases such as ALS, Alzheimer’s, Huntington’s, autism and 
many more. The Dailey lab has explored the roles of developing microglia in response to 
traumatic injury (Eyo et al., 2016), fetal alcohol syndrome (Ahlers et al., 2015), and stroke (Eyo 
et al., 2013). 
Microglia and Stroke: Specifically, our lab investigates microglia during ischemic stroke, which 
results when the flow of blood through an artery is restricted by a clot, thereby depriving the 
brain of essential nutrients and oxygen. This can cause extensive death of brain cells, a condition 
that can be debilitating or even fatal. Based on the most recent data, in 2015 ischemic stroke 
affected 18.7 million people, and killed 6.3 million people worldwide (Benjamin et al., 2018). To 
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combat this prevalent and potentially fatal condition, many neuroscientists have focused on 
protecting neurons during stroke, but recent work has also begun looking at the non-neuronal cell 
types of the brain, including microglial cells. During stroke, it is likely that microglia play 
diverse roles. On one hand, it appears that microglia might become overly activated during 
stroke, and this overactivation can cause potentially toxic neuroinflammation during stroke (Wu 
et al., 2012). However, there is also data to suggest that microglia might be helpful during stroke. 
Some studies in animal models of ischemic stroke demonstrate that microglial ablation worsens 
stroke outcomes, but reintroducing microglia improves stroke outcomes (Lalancette-Herbert et 
al., 2007). Overall, it is likely that microglia are not only either deleterious or protective during 
stroke, but a combination of both. It could be possible that microglia could trigger toxic amounts 
of inflammation that is deleterious to the brain early in stroke, but they are also required to 
phagocytose debris to help the brain recover after an ischemic insult.  
We have previously shown that microglial cells die during experimental stroke in excised 
neonatal mouse brain tissues (Eyo and Dailey, 2012), and in recent years our lab has studied the 
mechanisms that might govern this cell death. Although microglia play a complex role in both 
helping and harming the brain during stroke, as mentioned before it seems to be that the presence 
of microglia does improve outcomes. Therefore, protecting microglia may be an effective 
therapeutic strategy when treating stroke patients.  
Specifically, our lab has been studying the role of purinergic signaling in microglial cell 
death because it is also known that stroke causes an increase in extracellular ATP concentrations 
in the brain (Melani et al., 2005) as either live cells release ATP, or cells undergo apoptosis or 
necrosis, lyse and release their cellular contents. When our lab investigated the potential effects 
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of this increased ATP concentration on microglial cells during stroke, we found a mechanism by 
which ATP appears to trigger microglial cell death (Eyo et al., 2013).  
This experiment demonstrated that ATP might be one factor controlling microglial cell 
death during stoke. However, my specific project instead focuses on a metabolite of ATP, 
adenosine. As ATP concentrations rise in the brain during stroke, ectonucleotidases present 
throughout the brain (Langer et al., 2008) convert ATP to adenosine. My goal was to build on 
our understanding of how extracellular purines present during stroke might regulate microglial 
survival, by focusing now on adenosine. Preliminary evidence gathered by a previous graduate 
student working in an excised hippocampal tissue slice model of stroke suggested that adenosine 
might be protective to microglial cells during stroke-like conditions in brain tissues (Eyo & 
Dailey, unpublished). My first goal was to determine if this phenomenon also held true in an in 
vitro cell culture model, where we could study the effect of adenosine on microglia-like cells in 
isolation, without the other cells of the brain present to serve as potential confounding factors. 
Next, I set out to study the mechanism of this protective effect by focusing on the role of specific 
adenosine receptors present on microglia.  
Adenosine Receptors: In recent decades, many studies focused on the effects of different 
adenosine receptors on microglia function. There are four different adenosine receptors (A1, 
A2A, A2B and A3), all of which are G-protein coupled receptors. Pharmacological studies have 
shown that microglia seem to respond to different drugs which specifically target the A1, A2A, 
and A3 adenosine receptors, and current literature assumes that these three receptors are 
therefore expressed by microglia (Hasko et al., 2005). By pharmacologically targeting these 
different adenosine receptors in the brain, different groups have shown that different adenosine 
receptors seem to be responsible for different microglial activities. For example, the A1 receptor 
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seems to attenuate microglial activation, and also prevents the classic calcium influx seen in 
microglial cells treated with ATP (Luongo et al., 2014). The A2A receptor seems to promote the 
secretion by microglia of proinflammatory factors such as nitric oxide (Saura et al., 2005) and 
cyclooxygenase-2 (Fiebich et al., 1996), although an A2A receptor agonist is also under 
investigation as a potential treatment for stroke (Melani et al., 2014). Activation of the A3 
receptor seems to reduce microglial activation, and also improves outcomes after a model of 
subarachnoid hemorrhage (Luo et al., 2010). Additionally, a recent study showed that the A2B 
receptor appeared to exert some level of control over microglial IL-10 production (Koscso et al., 
2012), although previous literature suggested that it was not expressed on microglia (Hasko, 
2005). 
 The different roles of adenosine receptors on microglia, as described above, have made 
them critical targets for the treatment of stroke. They seem to play important roles in regulating 
microglial activation, and therefore inflammation in the brain overall, and different agonists and 
antagonists have already been investigated as potential treatments for stroke. Therefore, after 
finding that our first hypothesis was supported, as shown in results presented below, and 
microglial cells were protected from stroke-induced cell death by extracellular adenosine, our 
next goal was to target specific receptors. If we could find a specific receptor, or set of receptors, 
responsible for this effect, we could both connect it to existing literature about the function of 
different microglial adenosine receptors, and also be able to identify a single receptor or set of 
receptors as potential therapeutic targets. This latter goal would allow us to pinpoint the receptor 
that appears to protect microglial cells, which would make any treatment developed in the future 




MATERIALS AND METHODS 
Cell Culture: We used a line of microglia-like cells isolated from a neonatal rat brain, known as 
highly proliferating immortalized cells, or HAPI cells. These HAPI cells were generously 
provided by the Doorn Lab at the University of Iowa. These cells were reported to respond to 
inflammatory insults in a similar manner to microglial cells and were therefore considered to be 
an adequate cell culture model of microglia (Cheepsunthorn et al., 2001). However, due to 
variability within this cell line and inconsistent results in our experiments, our lab also used BV-
2 cells, which were also generously donated by the Doorn lab. These BV-2 cells were generated 
by Blasi et al. in 1990 by injecting isolated murine microglial cells with a v-raf / v-myc oncogene 
to create an immortalized line of microglia-like cells. In a recent review of this cell line, Henn et 
al. (2009) identified these cells as an acceptable substitute for primary microglial cells in in vitro 
experiments. Both of these cell lines were stored in a liquid nitrogen tank until thawing, at which 
point they were maintained in a Dulbecco’s Modified Eagle Medium (DMEM) solution with 
10% heat inactivated fetal bovine serum, 100 U/ml penicillin and 100 ug/ mL streptomycin in a 
37°C CO2 incubator as described in Eyo et al. (2013). These cells were re-plated in petri dishes at 
a 1:10 dilution after three days in the incubator to maintain the line or at a 1:1000 dilution in a 48 
well plate for experiments. After plating, cells were grown for 48 hours before experiments were 
started. 
Experimental Media Preparations: During the simulated stroke (oxygen glucose deprivation, or 
OGD) experiments, the BV-2 and HAPI cells were treated as described in Eyo and Dailey 
(2012). For control conditions, we used a solution of artificial cerebrospinal fluid (ACSF: NaCl, 
124; KCl, 3; NaH2PO4, 1.3; MgCl2, 3;HEPES, 10; CaCl2, 3; glucose, 10, all in mM). For our OGD 
condition, we generated modified ACSF using sucrose instead of glucose to deprive the cells of 
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metabolizable sugar, and nitrogen was bubbled through the media for 15 minutes. Based on 
preliminary results gathered by a graduate student (U. Eyo), we used a concentration of 500 uM 
adenosine, and all other adenosine receptor agonist and antagonist concentrations were 
determined based on manufacturing recommendations and adenosine receptor pharmacological 
studies (Klotz et al., 1997). All conditions also contained Hoechst stain (1:2000) and Sytox 
Orange (1:10,000) to image total cell nuclei and dead cell nuclei, respectively. Immediately 
before applying the solutions to the cells, we measured the pH of the acidic solutions and 
adjusted to 7.4. We exchanged the DMEM media for the given ACSF-based solution, sealed the 
well plates with Parafilm, and incubated at 37°C in a warm box. The experimenter was blinded 
to all of the conditions. After four hours, cells were transported to a florescent microscope to 
image and count the nuclei, with great care taken to transport these cells so as to not shake the 
plate and potentially dislodge loosely-adherent dead/dying cells. 
Image Acquisition and Processing: We captured images of these cells at 10x magnification 
while they were under a stage warmer set to 37°C, and all image acquisition took place within 
one hour per 48 well plate. In a 48 well plate, there were 24 wells in use, with 6 wells per 
condition, and we imaged each individual well in three different locations using two channels 
(DAPI and TRITC) to image Hoechst Stain and Sytox Orange, respectively. We determined the 
three different locations per well to image based on which areas contained the highest cell 
density. The images were then processed using ImageJ, and we created a specific Macro to auto-
local threshold the image and count the different nuclei based on size (0.00-0.20) and circularity 
(0.25-1.00). The automation of this analysis was intended to further reduce any potential bias or 
error from the experimenter. This procedure for image acquisition and processing is shown in 




Figure 1: Method of image processing and automated analysis to determine the number of 
dead cells in BV-2 cell cultures.  A) a transmitted light image of BV-2 cells, overlaid with a 
fluorescent Hoechst stain channel in blue; B) Hoechst stain alone; C) the Hoechst stained image 
after processing in ImageJ. Each circled area in the bottom image represents one cell nucleus 
counted by ImageJ, which were then summed to calculate the total number of cells. The same 








 To determine the raw cell nuclei numbers, we summed the number of total cell nuclei 
(shown by the Hoechst-stained nuclei) in the three different locations within the well together, 
and then summed the total number of dead cell nuclei (labeled by Sytox Orange) within the three 
different locations of the well together. The sum of the dead cell nuclei from the three different 
locations were divided by the sum of the total cell nuclei from the different locations to generate 
a cell death ratio. Within each experiment there were six cell death ratios (one per well), and we 
conducted three to four experiments within each main result shown below. Statistical 
significance of each experiment was determined in GraphPad Prism using a one-way ANOVA 





Effect of Exogenous Adenosine on Microglia-like Cells: First we attempted to recapitulate and 
extend the preliminary data gathered by graduate student Ukpong Eyo. As mentioned earlier, 
these data suggested that in a hippocampal slice model of stroke exogenous adenosine appeared 
to decrease microglial cell death. In this follow up experiment, we used an in vitro model of 
microglia to see if this held true when microglia-like cells (HAPI cells) were isolated from the 
rest of the brain. We saw no significant difference (p>0.05) between the control ACSF without 
adenosine and the control ACSF condition with adenosine, but it did appear that there was a 
slight reduction when adenosine was added to the control ACSF, with the average decreasing 
from 0.126 +/- 0.052 to 0.091 +/- 0.034. We first found that our model of stroke (oxygen glucose 
deprivation, or OGD) appeared to be successful at causing microglial cell death, increasing the 
cell death ratio from 0.126 +/- 0.052 in control ACSF to 0.400 +/- 0.109 in OGD ACSF. 
Additionally, 500 uM adenosine decreased cell death when added to the OGD ACSF, decreasing 
the amount of cell death back to 0.169 +/- 0.064, which was significantly (p<0.0001) different 
from the OGD condition, and it brought cell death down even to a level that was not significantly 
different from the control condition (p>0.05) (Figure 2 and 3). Next, we tested the effect of 
different adenosine receptor agonists and antagonists to determine if any Ado receptor is 
necessary or sufficient to cause the protective effect.  
A1 and A2A Receptors are Not Sufficient to Protect Microglia-like Cells: We first targeted the 
A1 receptor using the A1 receptor agonist 2-Chloro-N6-cyclopentyladenosine (CCPA). If 
activation of the A1 receptor is sufficient to protect microglia against OGD, then we would 




Figure 2: Application of extracellular adenosine reduces OGD-induced cell death. 
Simulated ischemia (OGD) increases cell death ratio relative to control (p<0.0001), 
and this OGD-induced cell death is significantly reduced (p<0.0001) by Adenosine 
(500 uM). One-way ANOVA with Tukey’s test for multiple comparisons, SD shown, 
n=18. * for 0.05>p>0.005, ** for 0.005>p>0.0005, *** for 0.0005>p>0.0001, **** 









Figure 3: Fluorescent images of HAPI cell nuclei. A/A’ is Control, B/B’ is OGD, 
C/C’ is OGD with 500 µM adenosine. A,B,C show the merged images of the DAPI 
labeled nuclei (red channel, representative of total cell nuclei) and the Sytox Orange 
labeled nuclei (green channel, representative of dead cell nuclei). A’, B’ and C’ shows 




cells) from OGD-induced cell death. However, when we applied CCPA (35 nM) to the BV-2 
cells we saw no significant (p>0.05) difference in cell death ratio between the OGD + CCPA 
condition (0.544 +/- 0.114) and the OGD condition on its own (0.608 +/- 0.160). However, there 
was a significant difference between both the OGD and the Control (<0.0001) and the OGD + 
CCPA and the Control (0.0003) and also the OGD + CCPA and OGD + Adenosine (0.0057) 
conditions. There was no significant difference between the Control and the OGD + Adenosine 
condition (Figure 4). Together, these data suggest that adenosine is protective for microglia-like 
cells in simulated stroke, cell-autonomously, even in a microglia-like cell line.  However, 
activation of the A1 receptor alone is not sufficient to cause this protective effect.  
We found similar results when we tested the effects of the adenosine receptor A2A agonist 
CGS 21860 (200 nM) (Figure 5). We saw relatively low levels of cell death within the Control 
and OGD + Adenosine conditions (0.125 +/- 0.031 and 0.084 +/- 0.029, respectively) which 
were not significantly different (p>0.05) from each other. There was a significant increase in the 
OGD condition, with the cell death ratio increasing to 0.229 +/- 0.087. However, the A2A 
agonist was not sufficient to significantly (p>0.05) reduce the amount of OGD induced cell 
death, with an average cell death ratio of 0.215 +/- 0.055.  Although these experiments seem to 
support our earlier conclusion that simulated ischemia can cause increased BV-2 cell death, and 
that exogenous adenosine application can reduce that cell death back to near-control levels, they 
also indicate that neither the A1 or A2A receptors are sufficient to cause this protective effect. 
A2A receptor is Not Necessary for Protective Effect: Next, we used adenosine receptor 
antagonists to determine which adenosine receptors may be necessary for protection. Thus far, 
we have only examined the effect of the adenosine A2A receptor, by using the A2A receptor 




Figure 4: A1 receptor agonist is insufficient to protect BV-2 cells. CCPA (35 
nM) alone is not sufficient to cause a significant difference between the OGD 
condition and the OGD + CCPA condition (p=0.5862). One-way ANOVA with 




Figure 5: A2A receptor agonist is insufficient to protect BV-2 cells. CGS (200 nM) 
alone is not sufficient to cause a significant difference between the OGD condition 
and the OGD + CGS condition (p=0.9538). One-way ANOVA with Tukey’s test for 




that a protective effect of adenosine is blocked when the antagonist is added to the solution, and 
that despite the presence of the previously protective adenosine the cell death is comparable to 
the OGD condition alone. However, although we saw that there was a low and statistically 
insignificant different amount of cell death between the Control (0.191 +/- 0.052) and OGD + 
Adenosine (0.247 +/- 0.014) conditions, and that OGD caused significantly increased amounts of 
BV-2 cell death (0.377 +/- 0.135), when we added the A2A antagonist to the OGD + Adenosine 
condition there was no significant difference between it (0.265 +/- 0.085) and the OGD + Ado 
condition (0.9172) (Figure 6). Although this supports our hypothesis surrounding the toxic 
effects of OGD on BV-2 cells and the protective effects of adenosine on BV-2 cells in this OGD 
condition, this specific experiment also suggests that the A2A receptor alone is not necessary to 







Figure 6: A2A receptor antagonist is insufficient to block protective effect. ZM (2 nM) 
alone is not sufficient to cause a significant difference between the OGD + Adenosine (Ado) 
condition and the OGD + Ado + ZM condition (p=0.917). One-way ANOVA with Tukey’s 








The previously described studies supported our initial hypothesis that extracellular 
adenosine protects microglial cells in stroke using an in vitro model of both microglia and stroke. 
All simulated stroke conditions significantly increased the amount of cell death relative to 
control, and the application of adenosine in these simulated stroke conditions significantly 
reduced this cell death relative to OGD alone. The adenosine application was so effective that in 
no condition was the OGD with adenosine condition significantly different from the control 
condition itself. This led us to the hypothesis that a specific adenosine receptor might be 
responsible for this observed protective effect. However, in these experiments we showed 
preliminary data that the A1 and A2A receptors are not sufficient to cause the protective effects 
of adenosine, and the A2A receptor is not necessary for this protective effect (Figure 7). With 
that said, throughout these experiments we struggled with the variability of immortalized cell 
lines (discussed in detail later), which could limit the validity of these results.  
High Throughput Screening: Additionally, we still do not know whether the A1, A2B or A3 
receptors are necessary for this effect, or if the A2B or A3 receptors are sufficient to cause this 
protective effect. To begin to test these different receptor subtypes in a time efficient manner, it 
would be advantageous to use large scale methods of collecting data. This would allow us to not 
only test the remaining receptors, but also potentially screen different combinations of agonists 
and antagonists. We therefore partnered with the High Throughput Screening Facility (HTSF) 
and Professor Meng Wu in the College of Pharmacy to design large scale experiments to test a 
large array of different agonists and antagonists in parallel. First of all, this ideally would allow 








although the trends between the different conditions stayed relatively constant, the absolute 
values of the cell death ratios varied drastically. Ideally, performing all of our experiments in one 
96 well plate (which the HTSF offered) could reduce some of that variation. Additionally, it is 
likely that if extracellular signaling might be controlling this effect, it might be more than one 
different adenosine receptor subtype that is necessary or sufficient for this effect. By using the 
HTSF, we could design experiments to create more combinations of adenosine receptor agonists 
and antagonists, to see if any were working cooperatively to create the observed protective 
effect. Finally, if we were able to create a model in the HTSF for simulating stroke-like 
conditions with these microglia-like cells, it could serve as a novel way to screen different stroke 
therapeutics targeting microglial cells. However, after doing a preliminary experiment in the 
HTSF, we found that the amount of variability we observed with the HAPI cells created too 
much variation to get any statistically significant results with the methods of analysis they used 
(Z-factor tests). We encountered the same problems with variability when we attempted to create 
a dose response curve, where the amount of conditions needed also increased the variability to a 
point that all statistical tests were nonsignificant. Therefore, future studies will need to determine 
how to reduce that variability.  
Primary Microglial Cells: One potential method to reduce the problem of variability is to find a 
different model of microglial cells. Microglial cells, and macrophages in general, are notoriously 
hard to keep in culture for long periods of time, and immortalized cells in general have a 
tendency to accrue additional mutations as they progress through rounds and rounds of passages. 
Our lab has been conducting most of our experiments in immortalized microglia-like cell lines 
(BV-2 and HAPI cells) and tissue slices, but we have never before attempted to isolate microglia 
directly from mouse brains. However, after a summer internship obtaining and using murine 
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isolated microglia (or primary microglia), I was able to bring that procedure back to the Dailey 
lab with the support of the Weiner lab’s perfusion tools. I am currently working on the first 
rounds of OGD experiments using these primary microglial cells, and with the goal of reducing 
variability through these new cells. Hopefully these cells will be more homogenous, since they 
have fewer opportunities to develop confounding mutations, and hopefully they will also die 
more robustly during OGD, given that they have not had the chance to adapt to the already 
slightly hypoxic/ glucose-deprived conditions present in cell culture incubation. This should 
ideally reduce the variability within our experiments.  
In vivo Future Directions: These in vitro experiments described above have the benefit of 
isolating microglia and microglia-like cells, so that our lab can investigate the mechanisms by 
which extracellular adenosine acts on these cells alone. This is great for elucidating basic 
mechanisms that might govern how we can regulate microglial cell death in the brain during 
stroke. However, to actually apply any of this to the brain of a stroke patient, we would need to 
see how targeting different adenosine receptors affects the brain in its entirety. This would mean 
looking at the effects of whatever specific adenosine receptor agonists and antagonists we can 
identify in these in vitro approaches that seem to affect microglial cell death, on an in vivo model 
of stroke. One method we could do which has previously been performed by collaborators of our 
lab is middle cerebral artery occlusion (MCAO), which is where a thin filament is threaded into 
the middle cerebral artery to simulate the stoppage of blood that occurs during ischemic stroke. 
We could then apply the identified adenosine agonists and antagonists to determine how they 
affect the microglia and other brain cells during stroke. This would give us a more general view 
of how targeting any mechanism that protects microglia might also cause side-effects to other 
brain cells.  
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 Clinical Relevance: The ultimate way this might be relevant to patients in clinic is if we could 
protect the microglial cells of the CNS from stroke-induced cell death, so that these cells could 
be allowed to play their role in protecting the brain from infection after stroke and helping to 
clear away harmful debris. However, our lab is also working on different nanoparticle 
conjugated anti-inflammatory drugs that might also work to reduce microglial inflammation 
during stroke. If we could develop a way to simultaneously protect microglial cells from death 
during stroke and reduce the amount of potentially neurotoxic pro-inflammatory chemicals they 
might be releasing, we might be able to improve patient outcomes by targeting the immune cells 
of the CNS. With that said, any potential therapy that might arise from our work would only be 
possible far in the future. Our main question right now is first being able to grasp the mechanism 
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